DOCSLIB.ORG

Revised Tentative Report of the Cosmetic Ingredient Review Expert Panel Safety Assessment of Alcohol Denat. Including SD Alcohol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Revised Tentative Report of the Cosmetic Ingredient Review Expert Panel Safety Assessment of Alcohol Denat. Including SD Alcohol Revised Tentative Report of the Cosmetic Ingredient Review Expert Panel Safety Assessment of Alcohol Denat. including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C and the denaturants Denatonium Benzoate, Quassin, and Brucine Sulfate/Brucine April 22, 2005 All interested persons are provided 90 days from the above date to comment on this Revised Tentative Safety Assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings , will be available at the CIR office for review by any interested party, and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. F. Alan Andersen. This safety assessment will again be considered at the September 12-13, 2005 meeting of the CIR Expert Panel. The 2005 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is F. Alan Andersen, Ph.D. Cosmetic Ingredient Review 1101 17th Street, NW, Suite 310 " Washington, DC 20036-4702 " ph 202.331.0651 " fax 202.331.0088 " [email protected] TABLE OF CONTENTS INTRODUCTION .................................................................... 1 PART I: DENATURANTS ............................................................. 2 CHEMISTRY ....................................................................... 3 Definition and Structure ........................................................ 3 Quassin .............................................................. 3 Brucine Sulfate......................................................... 4 Denatonium Benzoate ................................................... 5 Method of Manufacture......................................................... 7 Quassin .............................................................. 7 Brucine ............................................................... 8 Denatonium Benzoate ................................................... 8 Analytical Methods ............................................................ 8 Quassin .............................................................. 8 Brucine ............................................................... 9 Denatonium Benzoate ................................................... 9 Impurities.................................................................... 9 Brucine .............................................................. 10 Quassin ............................................................. 10 Denatonium Benzoate .................................................. 10 USE ............................................................................. 10 Cosmetic ................................................................... 10 Non-Cosmetic ............................................................... 12 GENERAL BIOLOGY................................................................ 20 Absorption, Metabolism, and Distribution.......................................... 20 Quassin ............................................................. 20 Lidocaine ............................................................ 20 Anti-feedant and Insecticidal Activity ............................................. 20 Quassin ............................................................. 20 Cytotoxicity ................................................................. 21 Brucine and Quassin ................................................... 21 TOXICOLOGY ..................................................................... 22 Acute Oral Toxicity ........................................................... 22 Quassin ............................................................. 22 Brucine .............................................................. 22 Denatonium Benzoate .................................................. 22 Acute Inhalation Toxicity....................................................... 23 Denatonium Benzoate .................................................. 23 Acute Ocular Toxicity ......................................................... 23 Denatonium Benzoate .................................................. 23 Acute Parenteral Toxicity ...................................................... 23 Quassin ............................................................. 23 Brucine .............................................................. 24 Short-Term Toxicity .......................................................... 24 Quassin ............................................................. 24 Chronic Toxicity ............................................................. 24 Denatonium Benzoate .................................................. 24 Dermal Irritation ............................................................. 25 Denatonium Benzoate .................................................. 25 Genital Irritation.............................................................. 26 Denatonium Benzoate .................................................. 26 REPRODUCTIVE AND DEVELOPMENTAL TOXICITY..................................... 26 Quassin ............................................................. 26 Lidocaine ............................................................ 27 MUTAGENICITY ................................................................... 27 Brucine .............................................................. 27 CARCINOGENECITY ............................................................... 28 Denatonium Benzoate .................................................. 28 CLINICAL ASSESSMENT OF SAFETY ................................................. 28 Dermal Sensitization and Irritation ............................................... 28 Brucine .............................................................. 28 Denatonium Benzoate .................................................. 31 Taste Aversion .............................................................. 33 Denatonium Benzoate .................................................. 33 Photoallergy ................................................................ 34 Denatonium Benzoate .................................................. 34 Brucine Sulfate........................................................ 35 Phototoxicity ................................................................ 36 Denatonium Benzoate .................................................. 36 Brucine Sulfate........................................................ 36 Case Studies................................................................ 37 Denatonium Benzoate .................................................. 37 PART II: ETHANOL ................................................................. 39 CHEMISTRY ...................................................................... 39 Definition and Structure ....................................................... 39 Chemical and Physical Properties ............................................... 39 Method of Manufacture........................................................ 39 Analytical Methods ........................................................... 39 Impurities................................................................... 39 USE ............................................................................. 40 Cosmetic ................................................................... 40 GENERAL BIOLOGY................................................................ 41 Absorption .................................................................. 41 Dermal .............................................................. 41 Distribution ................................................................. 42 Parenteral............................................................ 42 Inhalation ............................................................ 43 Oral................................................................. 44 Penetration Enhancement ..................................................... 44 ANIMAL TOXICOLOGY.............................................................. 46 Acute Toxicology............................................................. 46 Inhalation ............................................................ 46 .................................................................... 46 Ocular............................................................... 46 Short-Term Toxicity .......................................................... 46 Inhalation ............................................................ 46 Subchronic Toxicity .......................................................... 47 Oral................................................................. 47 Chronic Toxicity ............................................................. 47 REPRODUCTIVE AND DEVELOPMENTAL TOXICITY..................................... 48 Drosophila ........................................................... 48 Mice ................................................................ 48 Rats ................................................................ 49 Rabbits .............................................................
Load more

Recommended publications
  • US EPA Inert (Other) Pesticide Ingredients
    U.S. Environmental Protection Agency Office of Pesticide Programs List of Inert Pesticide Ingredients List 3 - Inerts of unknown toxicity - By Chemical Name UpdatedAugust 2004 Inert Ingredients Ordered Alphabetically by Chemical Name - List 3 Updated August 2004 CAS PREFIX NAME List No. 6798-76-1 Abietic acid, zinc salt 3 14351-66-7 Abietic acids, sodium salts 3 123-86-4 Acetic acid, butyl ester 3 108419-35-8 Acetic acid, C11-14 branched, alkyl ester 3 90438-79-2 Acetic acid, C6-8-branched alkyl esters 3 108419-32-5 Acetic acid, C7-9 branched, alkyl ester C8-rich 3 2016-56-0 Acetic acid, dodecylamine salt 3 110-19-0 Acetic acid, isobutyl ester 3 141-97-9 Acetoacetic acid, ethyl ester 3 93-08-3 2'- Acetonaphthone 3 67-64-1 Acetone 3 828-00-2 6- Acetoxy-2,4-dimethyl-m-dioxane 3 32388-55-9 Acetyl cedrene 3 1506-02-1 6- Acetyl-1,1,2,4,4,7-hexamethyl tetralin 3 21145-77-7 Acetyl-1,1,3,4,4,6-hexamethyltetralin 3 61788-48-5 Acetylated lanolin 3 74-86-2 Acetylene 3 141754-64-5 Acrylic acid, isopropanol telomer, ammonium salt 3 25136-75-8 Acrylic acid, polymer with acrylamide and diallyldimethylam 3 25084-90-6 Acrylic acid, t-butyl ester, polymer with ethylene 3 25036-25-3 Acrylonitrile-methyl methacrylate-vinylidene chloride copoly 3 1406-16-2 Activated ergosterol 3 124-04-9 Adipic acid 3 9010-89-3 Adipic acid, polymer with diethylene glycol 3 9002-18-0 Agar 3 61791-56-8 beta- Alanine, N-(2-carboxyethyl)-, N-tallow alkyl derivs., disodium3 14960-06-6 beta- Alanine, N-(2-carboxyethyl)-N-dodecyl-, monosodium salt 3 Alanine, N-coco alkyl derivs.
    [Show full text]
  • S. 1110, the Engine Coolant and Antifreeze Bittering Agent Act of 2005
    S. HRG. 109–377 S. 1110, THE ENGINE COOLANT AND ANTIFREEZE BITTERING AGENT ACT OF 2005 HEARING BEFORE THE SUBCOMMITTEE ON CONSUMER AFFAIRS, PRODUCT SAFETY, AND INSURANCE OF THE COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION UNITED STATES SENATE ONE HUNDRED NINTH CONGRESS FIRST SESSION JULY 18, 2005 Printed for the use of the Committee on Commerce, Science, and Transportation ( U.S. GOVERNMENT PRINTING OFFICE 27–356 PDF WASHINGTON : 2006 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate 0ct 09 2002 12:59 May 08, 2006 Jkt 027356 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 S:\WPSHR\GPO\DOCS\27356.TXT JACKF PsN: JACKF SENATE COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION ONE HUNDRED NINTH CONGRESS FIRST SESSION TED STEVENS, Alaska, Chairman JOHN MCCAIN, Arizona DANIEL K. INOUYE, Hawaii, Co-Chairman CONRAD BURNS, Montana JOHN D. ROCKEFELLER IV, West Virginia TRENT LOTT, Mississippi JOHN F. KERRY, Massachusetts KAY BAILEY HUTCHISON, Texas BYRON L. DORGAN, North Dakota OLYMPIA J. SNOWE, Maine BARBARA BOXER, California GORDON H. SMITH, Oregon BILL NELSON, Florida JOHN ENSIGN, Nevada MARIA CANTWELL, Washington GEORGE ALLEN, Virginia FRANK R. LAUTENBERG, New Jersey JOHN E. SUNUNU, New Hampshire E. BENJAMIN NELSON, Nebraska JIM DEMINT, South Carolina MARK PRYOR, Arkansas DAVID VITTER, Louisiana LISA J. SUTHERLAND, Republican Staff Director CHRISTINE DRAGER KURTH, Republican Deputy Staff Director DAVID RUSSELL, Republican Chief Counsel MARGARET L. CUMMISKY, Democratic Staff Director and Chief Counsel SAMUEL E.
    [Show full text]
  • Denatonium Capsaicinate and Methods of Producing the Same
    Europäisches Patentamt *EP001015418B1* (19) European Patent Office Office européen des brevets (11) EP 1 015 418 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07C 237/04, A01N 37/44, of the grant of the patent: A61K 31/165, C09D 7/12 26.05.2004 Bulletin 2004/22 (86) International application number: (21) Application number: 98937289.1 PCT/US1998/015836 (22) Date of filing: 31.07.1998 (87) International publication number: WO 1999/015495 (01.04.1999 Gazette 1999/13) (54) DENATONIUM CAPSAICINATE AND METHODS OF PRODUCING THE SAME DENATONIUM CAPSAICINAT UND VERFAHREN ZU IHRER HERSTELLUNG DENATONIUM CAPSAICINATE ET SES METHODES DE PRODUCTION (84) Designated Contracting States: • ROITBERG, Michael AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Highland Park, NJ 08904 (US) MC NL PT SE (74) Representative: Guerre, Dominique et al (30) Priority: 19.09.1997 US 929621 Cabinet Germain et Maureau, 12, rue Boileau, (43) Date of publication of application: BP 6153 05.07.2000 Bulletin 2000/27 69466 Lyon Cedex 06 (FR) (73) Proprietor: Burlington Bio-Medical & Scientific (56) References cited: Corp. EP-A- 0 458 177 WO-A-94/02558 Farmingdale, NY 11735-1718 (US) GB-A- 2 097 791 US-A- 4 005 038 US-A- 4 661 504 US-A- 4 997 853 (72) Inventors: US-A- 5 008 289 • BLUM, Melvin Wantagh, NY 11794 (US) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,150,782 B2 Lee Et Al
    US009 150782B2 (12) United States Patent (10) Patent No.: US 9,150,782 B2 Lee et al. (45) Date of Patent: Oct. 6, 2015 (54) FLUORESCENT TRACER FOR (56) References Cited WATER-SOLUBLE FILMS, RELATED METHODS, AND RELATED ARTICLES U.S. PATENT DOCUMENTS (71) Applicant: MONOSOL, LLC, Merrillville,- - - - IN (US) 2.477,3832,220,099 A 11/19407, 1949 GuentherLewis et al. (72) Inventors: David M. Lee, Crown Point, IN (US); (Continued) Stephen Bullock, Chicago, IL (US); Nicholas Zeese, Michigan City, IN (US) FOREIGN PATENT DOCUMENTS (73) Assignee: MONOSOL, LLC, Merrillville,- - - - IN (US) EP OO791680 197434 A2 10,8, 19971986 (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 0 days. Dye Tracing, Wikipedia Entry, downloaded from the Internet at (21) Appl. No.: 14/562,148 <http://en.wikipedia.org/wiki/Dye tracing> (page last modifed Apr. 26, 2014). (22) Filed: Dec. 5, 2014 (Continued) (65) Prior Publication Data Primary Examiner — Kiho Kim US 2015/O159082 A1 Jun. 11, 2015 (74) Attorney, Agent, or Firm — Marshall, Gerstein & Borun LLP Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 61/912,689, filed on Dec. Disclosed herein are fluorescent tracer compositions and 6, 2013. water-soluble polymer compositions containing fluorescent s compounds for tracing one or more components in the poly (51) Int. Cl. mer compositions. More particularly, the disclosure relates to GOIN 2L/64 (2006.01) fluorescent tracer compositions including a fluorophore and a C09K II/02 (2006.01) bitterant aversive component to be incorporated into a water soluble polymer composition Such as a water-soluble film.
    [Show full text]
  • Evaluation of the Fate and Transport of Methanol in the Environment
    EVALUATION OF THE FATE AND TRANSPORT OF METHANOL IN THE ENVIRONMENT Prepared For: American Methanol Institute 800 Connecticut Avenue, NW, Suite 620 Washington, DC 20006 Prepared By: Malcolm Pirnie, Inc. 180 Grand Avenue, Suite 1000 Oakland, California 94612 JANUARY 1999 3522-002 TABLE OF CONTENTS Page EXECUTIVE SUMMARY .............................................................................................ES-1 1.0 BACKGROUND .................................................................................................... 1 1.1 Purpose and Scope of Report........................................................................ 1 1.2 Introduction and History of Use ................................................................... 1 1.3 Methanol Production..................................................................................... 3 1.4 Chemical and Physical Properties................................................................. 4 1.5 Release Scenarios ......................................................................................... 5 1.6 Fate in the Environment ............................................................................... 7 2.0 PARTITIONING OF METHANOL IN THE ENVIRONMENT........................... 9 2.1 Methanol Partitioning Between Environmental Compartments .................. 9 2.2 Air/Water Partitioning.................................................................................. 9 2.3 Soil/Water Partitioning................................................................................
    [Show full text]
  • Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)
    Contains Nonbinding Recommendations Temporary Policy for Manufacture of Alcohol for Incorporation Into Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry March 2020 Updated February 10, 2021 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Pharmaceutical Quality/Manufacturing Standards (CGMP)/Over-the-Counter (OTC) Preface Public Comment This guidance is being issued to address the Coronavirus Disease 2019 (COVID-19) public health emergency. This is being implemented without prior public comment because FDA has determined that prior public participation for this guidance is not feasible or appropriate (see section 701(h)(1)(C)(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR 10.115(g)(2)). This guidance document is being implemented immediately, but it remains subject to comment in accordance with the Agency’s good guidance practices. Comments may be submitted at any time for Agency consideration. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Submit electronic comments to https://www.regulations.gov. All comments should be identified with the docket number FDA-2020-D-1106 and complete title of the guidance in the request. Additional Copies Additional copies are available from the FDA web page titled “ COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders,” available at https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease- 2019-covid-19, and from the FDA web page “Hand Sanitizers | COVID-19” available at: http://wcms-internet.fda.gov/drugs/coronavirus-covid-19-drugs/hand-sanitizers-covid-19.
    [Show full text]
  • Coagulation Treatment to Remove Denatonium Benzoate
    COAGULATION TREATMENT TO REMOVE DENATONIUM BENZOATE FROM WATER Thesis Submitted to The School of Engineering of the UNIVERSITY OF DAYTON In Partial Fulfillment of the Requirements for The Degree of Master of Science in Chemical Engineering By Hussein Alaydamee Dayton, Ohio May 2017 COAGULATION TREATMENT TO REMOVE DENATONIUM BENZOATE FROM WATER Name: Alaydamee, Hussein Hantoosh APPROVED BY: ___________________________ _________________________ Kenya Crosson, Ph.D. Kevin J. Myers, D.Sc., P.E. Advisory Committee Chairman Professor, Graduate Chemical Associate Professor Engineering Program Coordinator Department of Civil and Department of Chemical and Environmental Engineering and Materials Engineering Engineering Mechanics ________________________ Erick S. Vasquez, Ph.D. Assistant Professor Department of Chemical and Materials Engineering ________________________ ________________________ Robert J. Wilkens, Ph.D., P.E. Eddy M. Rojas Ph.D., M.A, P.E. Associate Dean for Research and Innovation Dean, School of Engineering Professor School of Engineering ii © Copyright by Hussein Hantoosh Alaydamee All rights reserved 2017 iii ABSTRACT COAGULATION TREATMENT TO REMOVE DENATONIUM BENZOATE FROM WATER Name: Alaydamee, Hussein Hantoosh University of Dayton Advisor: Dr. Kenya Crosson The bittering agent denatonium benzoate, DB, was mandated by the U.S. House of Representatives (H.R. 615) to be added to antifreeze containing more than 10% ethylene glycol at 30-50ppm in order to prevent accidental poisoning. 30-ppm DB concentration in water makes it unpalatable. This research addressed the optimal doses of alum and ferric chloride, and impact of water quality conditions such as pH, ionic strength, turbidity, and alkalinity on DB removal from water. Coagulation aids such as kaolin and bentonite were studied for their impact on DB removal.
    [Show full text]
  • AVMA Guidelines for the Euthanasia of Animals: 2020 Edition*
    AVMA Guidelines for the Euthanasia of Animals: 2020 Edition* Members of the Panel on Euthanasia Steven Leary, DVM, DACLAM (Chair); Fidelis Pharmaceuticals, High Ridge, Missouri Wendy Underwood, DVM (Vice Chair); Indianapolis, Indiana Raymond Anthony, PhD (Ethicist); University of Alaska Anchorage, Anchorage, Alaska Samuel Cartner, DVM, MPH, PhD, DACLAM (Lead, Laboratory Animals Working Group); University of Alabama at Birmingham, Birmingham, Alabama Temple Grandin, PhD (Lead, Physical Methods Working Group); Colorado State University, Fort Collins, Colorado Cheryl Greenacre, DVM, DABVP (Lead, Avian Working Group); University of Tennessee, Knoxville, Tennessee Sharon Gwaltney-Brant, DVM, PhD, DABVT, DABT (Lead, Noninhaled Agents Working Group); Veterinary Information Network, Mahomet, Illinois Mary Ann McCrackin, DVM, PhD, DACVS, DACLAM (Lead, Companion Animals Working Group); University of Georgia, Athens, Georgia Robert Meyer, DVM, DACVAA (Lead, Inhaled Agents Working Group); Mississippi State University, Mississippi State, Mississippi David Miller, DVM, PhD, DACZM, DACAW (Lead, Reptiles, Zoo and Wildlife Working Group); Loveland, Colorado Jan Shearer, DVM, MS, DACAW (Lead, Animals Farmed for Food and Fiber Working Group); Iowa State University, Ames, Iowa Tracy Turner, DVM, MS, DACVS, DACVSMR (Lead, Equine Working Group); Turner Equine Sports Medicine and Surgery, Stillwater, Minnesota Roy Yanong, VMD (Lead, Aquatics Working Group); University of Florida, Ruskin, Florida AVMA Staff Consultants Cia L. Johnson, DVM, MS, MSc; Director,
    [Show full text]
  • Ethylene Glycol Poisoning in a Child Treated with 4-Methylpyrazole
    Ethylene Glycol Poisoning in a Child Treated With 4-Methylpyrazole Patrick Harry, MD*; Eric Jobard, PhD‡; Maryvonne Briand, MD§; Alain Caubet, MDi; and Alain Turcant, PhD‡ ABSTRACT. Objective. The alcohol dehydrogenase acidosis. Another metabolite, oxalic acid, precipi- inhibitor 4-methylpyrazole (4-MP) is a new antidote of tates with calcium, leading to the formation of ethylene glycol (EG) intoxication. The purpose of the oxalate crystals and is responsible for the organ present case report was to demonstrate 4-MP efficiency toxicity of EG that results from the deposition of in EG poisoning in a 4-year-old child. oxalate crystals in tissues. EG poisoning is usually Method and Results. 4-MP Treatment was performed treated by gastric lavage performed promptly after 7 hours after EG ingestion. Plasma EG and 4-MP concen- trations were measured 2 hours after each infusion of the ingestion, alkalization, and administration of 4-MP. Plasma 4-MP concentrations were in the range of ethanol. In severe cases with acute renal failure, the values reported to block EG metabolism. The effi- the treatment include ethanol administration and ciency of 4-MP treatment was confirmed by the rapid hemodialysis to remove EG and its toxic metabo- correction of metabolic acidosis without alkalization and lites.2 The disadvantages of ethanol treatment are by the increase in EG half-life. No adverse effect of 4-MP the difficulty of maintaining ethanol blood levels was observed. in the range of 1 to 2 g/L by frequent adjustments Conclusion. This child ingested a potentially lethal of dosage2 and also the fact that ethanol may lead dose of EG despite a high concentration of bittering to a central nervous system depression, especially agent in antifreeze.
    [Show full text]
  • US EPA, Inert
    Inert Ingredients ordered alphabetically by Chemical Name Updated August 2004 CAS PREFIX NAME 1 (POE) 6 Tridecyl ether phosphate, reaction prod3 68954-84-7 (Poly(oxy-1,2-ethanediyl), alpha-nonylphenyl)-o 3 6798-76-1 Abietic acid, zinc salt 3 14351-66-7 Abietic acids, sodium salts 3 64-19-7 Acetic acid 4B Acetic acid ethenyl ester, polymer with carbon 26337-35-9 monoxide and ethene 4B Acetic acid ethenyl ester, polymer with ethanol and alpha-2-propenyl-omega-hydroxypoly(oxy- 137091-12-4 1,2-ethandiyl) 4B Acetic acid, [(5-chloro-8-quinolinyl)oxy]-, 1- 99607-70-2 methylhexyl ester (9CI) 4B 631-61-8 Acetic acid, ammonium salt 4B 123-86-4 Acetic acid, butyl ester 3 108419-35-8 Acetic acid, C11-14 branched, alkyl ester 3 90438-79-2 Acetic acid, C6-8-branched alkyl esters 3 108419-32-5 Acetic acid, C7-9 branched, alkyl ester C8-rich 3 Acetic acid, C9-11-branched alkyl esters, C10- 108419-34-7 rich 4B 62-54-4 Acetic acid, calcium salt 4A 2016-56-0 Acetic acid, dodecylamine salt 3 110-19-0 Acetic acid, isobutyl ester 3 127-08-2 Acetic acid, potassium salt 4A 127-09-3 Acetic acid, sodium salt 4A 108-24-7 Acetic anhydride 4B 141-97-9 Acetoacetic acid, ethyl ester 3 93-08-3 2'- Acetonaphthone 3 67-64-1 Acetone 3 75-05-8 Acetonitrile 2 98-86-2 Acetophenone 4B 828-00-2 6- Acetoxy-2,4-dimethyl-m-dioxane 3 32388-55-9 Acetyl cedrene 3 77-90-7 Acetyl tributyl citrate 4B 1506-02-1 6- Acetyl-1,1,2,4,4,7-hexamethyl tetralin 3 21145-77-7 Acetyl-1,1,3,4,4,6-hexamethyltetralin 3 61788-48-5 Acetylated lanolin 3 91994-94-4 Acetylated lanolin alcohol 4B 74-86-2
    [Show full text]
  • Chapter 5 Carboxylic Acids and Esters
    Chapter 5 Carboxylic Acids and Esters Chapter 5 Carboxylic Acids and Esters Chapter Objectives: • Learn to recognize the carboxylic acid, ester, and related functional groups. • Learn the IUPAC system for naming carboxylic acids and esters. • Learn the important physical properties of the carboxylic acids and esters. • Learn the major chemical reaction of carboxylic acids and esters, and learn how to predict the products of ester synthesis and hydrolysis reactions. • Learn some of the important properties of condensation polymers, especially the polyesters. Mr. Kevin A. Boudreaux Angelo State University CHEM 2353 Fundamentals of Organic Chemistry Organic and Biochemistry for Today (Seager & Slabaugh) www.angelo.edu/faculty/kboudrea Carboxylic Acids • Carboxylic acids are weak organic acids which contain the carboxyl group (RCO2H): O C O H O RCOOH RCO2H O condensed ways of RCOH writing the carboxyl group a carboxylic acid C H O the carboxyl group • The tart flavor of sour-tasting foods is often caused by the presence of carboxylic acids. 2 Chapter 5 Carboxylic Acids and Esters Nomenclature of Carboxylic Acids 3 Nomenclature of Carboxylic Acids • Select the longest carbon chain containing the carboxyl group. The -e ending of the parent alkane name is replaced by the suffix -oic acid. • The carboxyl carbon is always numbered “1” but the number is not included in the name. • Name the substituents attached to the chain in the usual way. • Aromatic carboxylic acids (i.e., with a CO2H directly connected to a benzene ring) are named after the
    [Show full text]
  • Combined Index to USP 42 and NF 37, Volumes 1–5, Including Second Supplement
    Combined Index to USP 42 and NF 37 Abaca-Aceto I-1 Combined Index to USP 42 and NF 37, Volumes 1±5, including Second Supplement Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 42±NF 37 and its First and Second Supplement. This index is repeated in its entirety in each volume. 1±2430 Volume 1 2431±4680 Volume 2 4681±6046 Volume 3 6047±7104 Volume 4 7105±8582 Volume 5 8583±9055 First Supplement 9057±9678 Second Supplement Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. butalbital and caffeine tablets, 630 and pentazocine tablets, 3433 A and caffeine tablets, 52 and pseudoephedrine hydrochloride capsules, 42 tablets, 73 Abacavir and (salts of) chlorpheniramine, oral solution, 43 oral solution, 21 dextromethorphan, and for effervescent oral solution, 44 sulfate, 25 pseudoephedrine, capsules containing at suppositories, 44 tablets, 22 least three of the following, 53 oral suspension, 45, 8619 and lamivudine tablets, 23 and (salts of) chlorpheniramine, tablets, 47 Abiraterone dextromethorphan, and extended-release tablets, 48 acetate, 27 pseudoephedrine, oral powder and tramadol hydrochloride oral acetate tablets, 28 containing at least three of the suspension, 4415 Absolute following, 55 Acetanilide, 6070 alcohol, 6071 and (salts of) chlorpheniramine, Acetate ether, 6070 dextromethorphan, and methyl, 6116 Absorbable pseudoephedrine, oral solution Acetate buffer, 6083 dusting powder, 1538 containing at least three of the TS, 6164 gelatin film, 2045 following, 58 Acetazolamide,
    [Show full text]